Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Sees Significant Growth in Short Interest

Key Points

• Short interest for Regeneron Pharmaceuticals increased by 20.4% from 2,350,000 to 2,830,000 shares as of August 31st, indicating growing bearish sentiment among investors.
• Regeneron Pharmaceuticals reported a quarterly EPS of $12.89, significantly exceeding the consensus estimate of $8.43, with a revenue of $3.68 billion for the quarter.
• The company declared a quarterly dividend of $0.88, translating to an annualized basis of $3.52, reflecting a yield of 0.6%.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) was the recipient of a significant growth in short interest in August. As of August 31st, there was short interest totaling 2,830,000 shares, a growth of 20.4% from the August 15th total of 2,350,000 shares. Currently, 2.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,010,000 shares, the short-interest ratio is currently 2.8 days. Based on an average daily trading volume, of 1,010,000 shares, the short-interest ratio is currently 2.8 days. Currently, 2.8% of the shares of the stock are short sold.

Regeneron Pharmaceuticals Stock Up 0.1%

NASDAQ REGN traded up $0.61 during trading on Monday, reaching $592.60. The company's stock had a trading volume of 50,259 shares, compared to its average volume of 1,094,223. Regeneron Pharmaceuticals has a 1-year low of $476.49 and a 1-year high of $1,154.56. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The business has a 50-day moving average price of $567.77 and a 200-day moving average price of $574.26. The stock has a market capitalization of $62.81 billion, a PE ratio of 14.93, a PEG ratio of 1.98 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping the consensus estimate of $8.43 by $4.46. The company had revenue of $3.68 billion during the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business's quarterly revenue was up 3.6% on a year-over-year basis. During the same period last year, the business earned $11.56 EPS. On average, research analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were paid a $0.88 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

Wall Street Analysts Forecast Growth

REGN has been the subject of several recent research reports. Argus lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. UBS Group restated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Rothschild & Co Redburn initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They issued a "buy" rating and a $890.00 price objective on the stock. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a "moderate buy" rating in a research report on Tuesday, September 2nd. Finally, Citigroup reaffirmed a "buy" rating and set a $650.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $817.67.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $31,000. Valeo Financial Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 51.3% in the second quarter. Valeo Financial Advisors LLC now owns 1,797 shares of the biopharmaceutical company's stock valued at $944,000 after acquiring an additional 609 shares in the last quarter. Osaic Holdings Inc. increased its position in shares of Regeneron Pharmaceuticals by 55.2% during the second quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company's stock worth $9,607,000 after purchasing an additional 6,073 shares in the last quarter. MASTERINVEST Kapitalanlage GmbH purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $1,138,000. Finally, Cim Investment Management Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 99.6% during the 2nd quarter. Cim Investment Management Inc. now owns 920 shares of the biopharmaceutical company's stock worth $483,000 after purchasing an additional 459 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.